Openbookopenbook
Equity
FOLD
+0.0 · +0.00%
USD · NASDAQ

Amicus Therapeutics Inc(FOLD) Stock Analysis | Healthcare

USD --+0.00%
Reward60Moderate
Risk41Moderate
75%Data
Thin -4% profit margin · Revenue growing 24% YoY
Growth Machine
Market Cap:4.50Bn
ⓘ
Reward Rating
60
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
41
Moderate
Risk Assessment
4 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on FOLD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for FOLD, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $14.50.

What is Amicus Therapeutics Inc?

, a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.

FOLD · Verdict

Solid reward · moderate risk

FOLD stands out on volatility and growth, but watch the valuation signal.

Based on 88% data coverage

FOLD · Verdict

What’s working & what to watch

Strengths 2

  • Volatility80/100

    Top decile vs peers

  • Growth78/100

    Rev +24.4% CAGR · earnings -51.4%

Watchouts 2

  • Valuation30/100

    P/E 17.6× · PEG 0.42

  • Balance sheet32/100

    Interest covered 1.0×

Model-based scoring. For information only — not financial advice.

What is Amicus Therapeutics Inc?

, a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 4.50B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (60)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

ASLTYMid Cap / 4.5B market cap
ASLTY
Compare
PBLSMid Cap / 4.5B market cap
Parabilis Medicines, Inc. Common Stock
Compare
CELCMid Cap / 4.6B market cap
Celcuity LLC
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap4.50B
P/E RatioN/A
Dividend YieldN/A
Beta0.429
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
5218,798 shares
$2.7M
0
9-12months
6201,652 shares
$2.0M
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.